George Kemble - 14 Aug 2026 Form 4 Insider Report for Sagimet Biosciences Inc. (SGMT)

Reporting relationship: Director
Issuer ticker: SGMT
Reported as of: 14 Aug 2026
Net transaction value: -$3,591,580
SEC form: 4
Accepted by SEC: 17 Aug 2026, 16:05:03 UTC
Prior SEC filing: 12 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Rozek, Attorney-in-Fact

Key filing fact

George Kemble filed Form 4 for Sagimet Biosciences Inc. (SGMT) on 17 Aug 2026.

Key facts

This page summarizes George Kemble's Form 4 filing for Sagimet Biosciences Inc. (SGMT).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Aug 2026, 16:05.

Change

Previous filing in this sequence was filed on 12 Aug 2026.
Current net transaction value: -$3,591,580.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001858176 Primary reporting owner

Kemble George

Relationship: Director
Address: SAGIMET BIOSCIENCES INC., 950 TOWER LANE, SUITE 1500, FOSTER CITY
Signature: /s/ Elizabeth Rozek, Attorney-in-Fact
Signature date: 17 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SGMT transaction

Series A Common Stock

Options Exercise

Transaction value
Shares: +326,618
Change %: +525%
Price: $6.36^*
Shares after: 388,779
Date: 14 Aug 2026
Ownership: Direct
Footnotes: F1

SGMT transaction

Series A Common Stock

Options Exercise

Transaction value
Shares: +24,369
Change %: +6.3%
Price: $6.36^*
Shares after: 413,148
Date: 14 Aug 2026
Ownership: Direct
Footnotes: F1

SGMT transaction

Series A Common Stock

Sale

Transaction value: $3,591,580
Shares: -350,987
Change %: -85%
Price: $10.23
Shares after: 62,161
Date: 14 Aug 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SGMT transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -326,618
Change %: -91%
Price: $0.000000^*
Shares after: 31,455
Date: 14 Aug 2026
Ownership: Direct
Underlying class: Series A Common Stock
Underlying amount: 326,618
Exercise price: $6.36
Footnotes: F1, F3

SGMT transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -24,369
Change %: -68%
Price: $0.000000^*
Shares after: 11,608
Date: 14 Aug 2026
Ownership: Direct
Underlying class: Series A Common Stock
Underlying amount: 24,369
Exercise price: $6.36
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F3

This option is fully vested and exercisable as of the date hereof.